metaEvidence - overview


			DCR
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
versus paclitaxel
	avelumab alone vs. paclitaxel	1	0.37 [0.23; 0.60], 1 RCT, I2=0% statistically significant harm
	pembrolizumab alone vs. paclitaxel	1	-
versus placebo
	nivolumab alone vs. placebo	1	1.99 [1.24; 3.18], 1 RCT, I2=0% unassessable degree of certainty
mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive
versus paclitaxel
	pembrolizumab alone vs. paclitaxel	1	-